Evaluation of eltrombopag in patients with aplastic anemia in real-world experience.

ABSTRACT: Background:Although eltrombopag has recently been approved for treating AA, the effects of its clinical use remain unknown. Methods:We retrospectively analyzed 11 patients with AA, who had been treated with eltrombopag from August 2017 to May 2018. Results:Overall response rate was 55%. There was tri-lineage recovery in four patients and platelet recovery in two. The reactive time was within 8 weeks after treatment initiation. Stage at the initial assessment, the neutrophil-to-lymphocyte ratio and platelet counts were significantly different between the responders and non-responders. Conclusion:Eltrombopag is a promising agent for treating patients with any degree of AA.

SUBMITTER: Konishi A 

PROVIDER: S-EPMC6416522 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature